XOMA ROYALTY CORP. overview

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating XOMA Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire NEW YORK, Dec. 11, 2017 NEW YORK , Dec. 11, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of XOMA Corporation (NASDAQ: XOMA). If you are a shareholder of XOMA...

BERKELEY, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that it has established proof-of-concept for its product candidate 358 in congenital hyperinsulinism (CHI) and hypoglycemia post-bariatric surgery (PBS). The Company will host a webcast and conference call today, January 31, 2017, at 2:00 p.m. PST (5:00 p.m. EST) to share data from these studies. The CHI acute studies have met...

Up to $22 million in revenue generated through sale of royalty streams from two license agreements to HealthCare Royalty Partners, with an initial $18 million payment and up to $4 million in future milestones Non-dilutive funding to support clinical advancement of XOMA 358 in a streamlined manner Operational transformation eliminates 57 positions Significantly reduced operating expense structure going forward Jim Neal named Chief Executive Officer and joins the Board of Directors, replacing John...

BERKELEY, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent achievements and financial results for the third quarter ended September 30, 2016. “In the third quarter, we accelerated activity in our XOMA 358 clinical trials in patients with hypoglycemia due to congenital hyperinsulinism (CHI) or post-bariatric surgery (PBS). In mid-September, we presented promising initial data...

Preclinical Data from XOMA’s Novel Anti-IL-2 Immuno-oncology Monoclonal Antibodies Program to be Presented at SITC Advancing Unique Functional Antibody Antagonists Targeting the Parathyroid Hormone Receptor 1 (PTH1R) Plan to Out-license IL-2 and PTH1R Programs to Fund Endocrine Efforts BERKELEY, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today unveiled its interleukin-2 (IL-2) monoclonal...

BERKELEY, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted in principle the Company’s proposal to initiate a multi-dose Phase 2 clinical study of XOMA 358 in children two years and older diagnosed with Congenital Hyperinsulinism (CHI). “MHRA officials clearly recognize the importance and...

BERKELEY, Calif., Oct. 14, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that, at a special meeting of the Company's stockholders held on October 14, 2016, its stockholders voted to approve a reverse stock split of the Company’s issued and outstanding common stock. XOMA’s Board of Directors then determined that the split would be at a ratio of 1-for-20. Upon the effectiveness of the reverse stock...